

Supplementary material

Table 1: Domain-specific Inclusion and Exclusion Criteria (1,2)

Domain	Inclusion criteria	Exclusion criteria
Antiviral	<ul style="list-style-type: none"> • Active COVID-19 infection with cycle threshold (Ct) value <30 times 	<ul style="list-style-type: none"> • 30 ml/min≤creatinine clearance<60ml/min • Severe liver dysfunction (Child-Pugh C) • known or suspected pregnancy will result in exclusion from any intervention that include Paxlovid or Azvudine • Known hypersensitivity to an agent specified as an intervention in this domain will exclude a patient from receiving that agent • Known HIV infection will exclude a patient from receiving Paxlovid or Azvudine • Known hypersensitivity to Paxlovid or Azvudine •Receiving Salmeterol, Rifampicin, Tacrolimus, Sirolimus, Domperidone, Simvastatin, Rivaroxaban, Estazolam, Atorvastatin, Amiodarone, Propafenone, Carbamazepine as usual medications prior to this hospitalization or any administration of drugs mentioned above within 72 hours prior to assessment of eligibility will exclude a patient from receiving Paxlovid

<p>Immune modulation</p>	<ul style="list-style-type: none"> • Active COVID-19 infection • The level of IL-6 in serum was 100pg/ml and more (10 times more than upper limit of reference) • C-reactive protein ≥ 75 mg/L 	<ul style="list-style-type: none"> • Patient has already received any dose of one or more of any form of α-thymosin, Baricitinib or Tocilizumab during this hospitalization or is on long-term therapy with any of these agents prior to this hospital admission • Known condition or treatment resulting in ongoing immune suppression including neutropenia prior to this hospitalization • The treating clinician believes that participation in the domain would not be in the best interests of the patient • Known hypersensitivity to an agent specified as an intervention in this domain • Known or suspected pregnancy will result in exclusion from α-thymosin, Tocilizumab and Baricitinib interventions. • A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal will result in exclusion from receiving Tocilizumab • A baseline platelet count < 50x10⁹/L, or neutrophil < 0.5 x10⁹/L will result in exclusion from receiving Tocilizumab • Active tuberculosis, malignant tumor, thrombus, pregnancy will result in exclusion from receiving Baricitinib
---------------------------------	---	--

		<ul style="list-style-type: none"> • Patients who suffered from thymoma or who received organ transplantation will result in exclusion from receiving Baricitinib
Intravenous immunoglobulin	<ul style="list-style-type: none"> • Active COVID-19 infection 	<ul style="list-style-type: none"> • More than 14 days have elapsed since hospital admission • Patient has already received treatment with any non-trial prescribed antibody therapy (monoclonal antibody, hyperimmune immunoglobulin, or convalescent plasma) intended to be active against COVID-19 during this hospital admission • The treating clinician believes that participation in the domain would not be in the best interests of the patient • Known hypersensitivity to an agent specified as an intervention in this domain • Known previous history of transfusion-related acute lung injury • Known objection to receiving plasma products
Antiplatelet	<ul style="list-style-type: none"> • Pre-existing disorders need antiplatelet before COVID-19 infection. • Recommended for all patients with severe and critical illness 	<ul style="list-style-type: none"> • Clinical or laboratory bleeding risk or both that is sufficient to contraindicate antiplatelet therapy • Patient is already receiving antiplatelet therapy or non-steroidal anti-inflammatory drug (NSAID) or a clinical decision has been made to commence antiplatelet or NSAID therapy • Patients otherwise eligible for the therapeutic anticoagulation domain will be excluded from the

		<p>antiplatelet domain if age is more than 75 years</p> <ul style="list-style-type: none"> • Creatinine clearance <30ml/min, or receiving renal replacement therapy or ECMO • Known hypersensitivity to an agent specified as an intervention in this domain will exclude a patient from receiving that agent • Known or suspected pregnancy will result in exclusion from the P2Y12 inhibitor intervention • Administration or intention to administer Paxlovid will result in exclusion from the P2Y12 inhibitor intervention that are using ticagrelor as the P2Y12 inhibitor
<p>Anticoagulation</p>	<ul style="list-style-type: none"> • Pre-existing disorders need anticoagulation therapy before COVID-19 infection • Patients otherwise eligible for the therapeutic antiplatelet domain will be included if they already have received Paxlovid 	<ul style="list-style-type: none"> • Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy • Known or suspected previous adverse reaction to low molecular weight heparin (LMWH) including heparin-induced thrombocytopenia (HIT). • Patients with a platelet count of less than $50 \times 10^9/L$, hemoglobin level below 80 g/L, a bleeding history within the past 30 days, or a creatinine clearance of less than 30 ml/min will be excluded in therapeutic anticoagulation group • Patients with a platelet count of less than $50 \times 10^9/L$, a recent history of brain bleeding, or active

		bleeding who need more than 400ml of blood transfusion, or a creatinine clearance of less than 30 ml/min will be excluded in thromboprophylaxis group
Glucocorticoid	<ul style="list-style-type: none"> • PaO₂/FiO₂ and imaging of Chest CT deteriorated over time during hospitalization 	<ul style="list-style-type: none"> • Known hypersensitivity to dexamethasone or methylprednisolone • An indication to prescribe systemic glucocorticoid for a reason that is unrelated to the current episode, such as chronic corticosteroid use before admission, acute severe asthma, or suspected or proven <i>Pneumocystis jiroveci</i> pneumonia

Reference

1. Chinese Thoracic S, Chinese Association of Chest Physicians Critical Care G. [Expert consensus on treatment of severe COVID-19 caused by Omicron variants]. *Zhonghua Jie He He Hu Xi Za Zhi* 2023;46:101-10.
2. National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 10). in Chinese. 2022.

Table 2. Day 60 EQ VAS Results

		N	Mean (SD)	Median (IQR)
Antiviral domain				
	No antiviral therapy	456	69.5(14.9)	70(60-80)
	Paxlovid	241	64.4(16)	65(50-75)
	Azvudine	157	67.3(15.4)	70(60-80)
Immune modulation domain				
	No immune modulator	629	67.8(15.9)	70(60-80)
	α -thymosin	116	68.6(14.8)	70(60-80)
	Baricitinib	39	65.1(12.7)	65(55-75)
	IL-6 receptor antagonist	38	60(14.9)	52.5(50-70)
Immunoglobulin domain				
	No immunoglobulin	788	67.3(15.8)	70(60-80)
	Intravenous immunoglobulin	70	65.4(14)	70(50-75)
Anticoagulation domain				
	Thromboprophylaxis	528	67.4(15.1)	70(55-80)
	Therapeutic anticoagulation	121	62(16.3)	60(50-70)
Antiplatelet domain				
	No antiplatelet agent	234	72.5(15.1)	75(60-85)
	Antiplatelet agent	228	65.3(13.8)	65(55-75)
Glucocorticoid domain				
	No glucocorticoid	224	69.1(15.3)	70(60-80)
	Glucocorticoid	719	66.4(15.6)	70(55-80)

SD denotes standard deviation; IQR, interquartile range

Table 3. Day 60 Disability Categories

		Complete Disability n/N(%)	Severe Disability n/N (%)	Moderate Disability n/N (%)	Mild Disability n/N (%)	No Disability n/N (%)
Antiviral domain						
	No antiviral therapy	1/458(0.2)	175/458 (38.2)	112/458 (24.5)	155/458 (33.8)	15/458 (3.3)
	Paxlovid	3/236(1.3)	53/236 (22.5)	56/236 (23.7)	107/236 (45.3)	17/236 (7.2)
	Azvudine	1/157(0.6)	39/157 (24.8)	45/157 (28.7)	66/157 (42)	6/157 (3.8)
Immune modulation domain						
	No immune modulator	2/629(0.3)	201/629 (32)	144/629 (22.9)	249/629 (39.6)	33/629 (5.2)
	α-thymosin	2/117(1.7)	35/117 (29.9)	38/117 (32.5)	38/117 (32.5)	4/117 (3.4)
	Baricitinib	0/40(0)	9/40 (22.5)	5/40 (12.5)	25/40 (62.5)	1/40 (2.5)
	IL-6 receptor antagonist	0/36(0)	5/36(13.9)	6/36 (16.7)	23/36 (63.9)	2/36 (5.6)
Immunoglobulin domain						
	No immunoglobulin	3/785(0.4)	236/785 (30.1)	190/785 (24.2)	323/785 (41.1)	33/785 (4.2)
	Intravenous immunoglobulin	2/71(2.8)	20/71(28.2)	16/71(22.5)	29/71(40.8)	4/71(5.6)
Anticoagulation domain						
	Thromboprophylaxis	4/527(0.8)	162/527(30.7)	125/527(23.7)	209/527(39.7)	27/527(5.1)
	Therapeutic anticoagulation	0/120(0)	22/120(18.3)	30/120(25)	59/120(49.2)	9/120(7.5)
Antiplatelet domain						
	No antiplatelet agent	2/235(0.9)	128/235(54.5)	53/235(22.6)	46/235(19.6)	6/235(2.6)
	Antiplatelet agent	0/228(0)	53/228(23.2)	61/228(26.8)	103/228(45.2)	11/228(4.8)
Glucocorticoid domain						
	No glucocorticoid	0/223(0)	74/223(33.2)	57/223(25.6)	81/223(36.3)	11/223(4.9)
	Glucocorticoid	5/717(0.7)	205/717(28.6)	175/717(24.4)	298/717(41.6)	34/717(4.7)

Table 4: Day 60 Disability Comparison

	N (survivors at day 60)	WHODAS score, median (IQR) [N]	Adjusted odd ratio (95% CrI)	P value
Antiviral domain				
No antiviral therapy	458	86.5(59-132)	1.00(reference)	
Paxlovid	236	109(73-147)	0.45(0.32,0.62)	<0.001
Azvodine	157	102(71-141)	0.68(0.47,0.97)	0.034
Immune modulation domain				
No immune modulator	629	98(65-144)	1.00(reference)	
α-thymosin	117	92(67-124)	1.43(0.94,2.18)	0.095
Baricitinib	40	135.5(79-156)	0.68(0.33,1.37)	0.282
IL-6 receptor antagonist	36	120(99-133)	0.75(0.25,2.30)	0.621
Immunoglobulin domain				
No immunoglobulin	785	99(65-141)	1.00(reference)	
Intravenous immunoglobulin	71	102(67-143)	1.68(1.00,2.82)	0.052
Anticoagulation domain				
Thromboprophylaxis	527	99(65-141)	1.00(reference)	
Therapeutic anticoagulation	120	114.5(81-156)	0.65(0.44,0.96)	0.03
Antiplatelet domain				
No antiplatelet agent	235	69(56-102)	1.00(reference)	
Antiplatelet agent	228	107.5(75-144.5)	0.62(0.38,1.02)	0.06
Glucocorticoid domain				
No glucocorticoid	223	96(61-129)	1.00(reference)	
Glucocorticoid	717	101(68-145)	1.16(0.84,1.60)	0.355

IQR denotes interquartile range; CrI, credible interval

Odds ratio parameters are for the analysis of WHODAS disability category. An $OR < 1$ indicates reduced disability.

P value is computed from an ordinal mixture model